iZafe Group
iZafe Group AB is a Swedish health-tech company focused on digital medication management solutions for home care, healthcare providers, and consumers. Its core offering centers on connected pill dispensers, medication adherence tools, and related software and services sold through partner channels and direct consumer sales in selected markets.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueConnected medication dispenser and associated services for adherence monitoring.
Smart pillbox product used to support correct medication timing and adherence.
Recurring license fees from welfare and healthcare partners using iZafe solutions.
Direct-to-consumer subscriptions and device sales, mainly through online channels.
Customers
iZafe sells mainly through selected corporate partners with local market knowledge, including digital welfare and healthcare platform providers. It also serves public and private healthcare and welfare organizations, as well as consumers in the Swedish market through direct online sales. The common buying reason is to reduce medication errors and improve adherence in aging and chronic-care populations.
Buy iZafe products and licenses to embed adherence tools into their own care offerings.
Use Dosell and related tools to support medication management in home care and elder care.
Purchase digital medication solutions to improve service quality and workflow efficiency.
Buy subscriptions and devices directly for personal medication adherence support.
Strategy
iZafe’s strategy is to scale through local and regional partners that already have healthcare relationships, distribution capability, and market knowledge. The company also combines partner-led expansion with more direct control in selected markets, which can improve customer ownership and recurring revenue visibility. Its product strategy is centered on medication adherence across the patient journey, from connected dispensers to smart pillboxes and mobile applications.
Partners provide local market access, healthcare expertise, and distribution reach.
License and subscription models can improve predictability versus one-time device sales.
A wider product set increases relevance across different patient and care settings.
Geography
iZafe is headquartered in Stockholm and operates through partners across several European markets. The company reports active presence in Sweden, Norway, Finland, Iceland, the Netherlands, and Spain, with Sweden also serving as the main direct-to-consumer market. Its geography matters because adoption depends on local healthcare systems, distribution partners, and regulatory acceptance.
Risks
iZafe depends on partner execution, healthcare adoption, and market access in each country, so growth can be uneven and slower than direct-sales models. The business also faces product, regulatory, and reimbursement risk because medication-management tools must fit local care workflows and gain trust from providers and consumers. As a small health-tech company, it is additionally exposed to concentration risk, commercialization risk, and accounting judgment around revenue timing and asset values.
- Healthcare adoption and workflow integrationImpact: HighLikelihood: Medium
Medication-adherence tools must fit provider processes and gain user trust before scaling.
Exposure: Public and private care settings
- Dependence on partner channelsImpact: HighLikelihood: Low
The company relies on selected corporate partners for market access and sales execution.
Exposure: European partner markets
- Commercial concentrationImpact: High
A limited number of products, partners, and markets can make results sensitive to individual wins or losses.
Exposure: Company-wide
- Country-specific regulatory and reimbursement barriersImpact: MediumLikelihood: Medium
Digital health products often require local approvals, procurement acceptance, or reimbursement support.
Exposure: Nordics and Western Europe
Accounting
Judgemental itemsHardware, license, and subscription elements may be recognized at different points in time.
Impact: Affects revenue timing and quarterly comparability
Future commercialization assumptions are judgmental for a small product company.
Impact: Can materially affect balance sheet and earnings
Office and operational leases can change the presentation of operating expenses and liabilities.
Impact: Affects EBITDA-style metrics and leverage presentation
Similar listed companies
Publicly listed companies with a comparable business focus.
Pulmatrix, Inc.
PULM · Pharmaceutical Preparations
Isofol Medical
ISOFOL · Health Care
Isofol Medical AB is a Swedish biotechnology company focused on the development of arfolitixorin, a drug candidate aimed at improving treatment outcomes for metastatic colorectal cancer.
Axfood
AXFO · Consumer Staples
Axfood is a prominent player in the Swedish food retail market, operating a diverse range of grocery store concepts including Willys, Hemköp, and City Gross.
Avricore Health Inc.
AVCRF · Pharmaceutical Preparations
Ascelia Pharma
ACE · Health Care
Ascelia Pharma is a Swedish pharmaceutical company headquartered in Malmö, with a US base in New Jersey.
Jazz Pharmaceuticals plc
JAZZ · Pharmaceutical Preparations
Jazz Pharmaceuticals plc is a biopharmaceutical company focused on medicines for serious diseases, with a portfolio centered on neuroscience and oncology.
Last updated: 24/09/2026